Total Debt Summary of Evotec SE

Evotec SE's latest annual total debt in 2023 was 626.19 Million EUR , up 23.59% from previous year.
Evotec SE's latest quarterly total debt in 2024 Q2 was 473.51 Million EUR , down -24.55% from previous quarter.
Evotec SE reported annual total debt of 506.67 Million EUR in 2022, down -1.22% from previous year.
Evotec SE reported annual total debt of 512.91 Million EUR in 2021, up 4.26% from previous year.
Evotec SE reported quarterly total debt of 473.51 Million EUR for 2024 Q2, down -24.55% from previous quarter.
Evotec SE reported quarterly total debt of - EUR for 2023 Q1, down -100.0% from previous quarter.

Annual Total Debt Chart of Evotec SE (2023 - 2001)

Historical Annual Total Debt of Evotec SE (2023 - 2001)

Year	Total Debt	Total Debt Growth
2023	626.19 Million EUR	23.59%
2022	506.67 Million EUR	-1.22%
2021	512.91 Million EUR	4.26%
2020	491.96 Million EUR	6.23%
2019	463.09 Million EUR	304.58%
2018	114.46 Million EUR	-39.73%
2017	189.92 Million EUR	558.85%
2016	28.82 Million EUR	25.65%
2015	22.94 Million EUR	6.47%
2014	21.54 Million EUR	24.99%
2013	17.24 Million EUR	-0.93%
2012	17.4 Million EUR	4.12%
2011	16.71 Million EUR	30.28%
2010	12.82 Million EUR	-2.85%
2009	13.2 Million EUR	16.57%
2008	11.32 Million EUR	-2.86%
2007	11.66 Million EUR	-2.06%
2006	11.9 Million EUR	-10.3%
2005	13.27 Million EUR	405.7%
2004	2.62 Million EUR	46.2%
2003	1.79 Million EUR	0.0%
2002	- EUR	0.0%
2001	- EUR	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	627.55 Million EUR	0.22%
2024 Q2	473.51 Million EUR	-24.55%
2023 Q1	- EUR	-100.0%
2023 Q4	626.19 Million EUR	6.36%
2023 Q3	588.74 Million EUR	10.22%
2023 Q2	534.14 Million EUR	0.0%
2023 FY	626.19 Million EUR	23.59%
2022 FY	506.67 Million EUR	-1.22%
2022 Q1	518.56 Million EUR	1.1%
2022 Q3	492.09 Million EUR	1.86%
2022 Q4	506.67 Million EUR	2.96%
2022 Q2	483.12 Million EUR	-6.83%
2021 Q3	500.61 Million EUR	-2.39%
2021 Q1	517.07 Million EUR	5.1%
2021 FY	512.91 Million EUR	4.26%
2021 Q2	512.85 Million EUR	-0.82%
2021 Q4	512.91 Million EUR	2.46%
2020 Q3	454.66 Million EUR	-7.19%
2020 FY	491.96 Million EUR	6.23%
2020 Q1	459.4 Million EUR	-0.8%
2020 Q2	489.87 Million EUR	6.63%
2020 Q4	491.96 Million EUR	8.21%
2019 Q3	438.53 Million EUR	0.07%
2019 Q2	438.21 Million EUR	92.87%
2019 FY	463.09 Million EUR	304.58%
2019 Q4	463.09 Million EUR	5.6%
2019 Q1	227.2 Million EUR	98.5%
2018 FY	114.46 Million EUR	-39.73%
2018 Q2	156.46 Million EUR	-14.41%
2018 Q3	149.68 Million EUR	-4.33%
2018 Q1	182.8 Million EUR	-3.75%
2018 Q4	114.46 Million EUR	-23.53%
2017 Q3	171.72 Million EUR	2065.29%
2017 FY	189.92 Million EUR	558.85%
2017 Q1	8.32 Million EUR	-71.12%
2017 Q2	7.93 Million EUR	-4.74%
2017 Q4	189.92 Million EUR	10.6%
2016 FY	28.82 Million EUR	25.65%
2016 Q4	28.82 Million EUR	94.76%
2016 Q3	14.8 Million EUR	-18.66%
2016 Q2	18.19 Million EUR	-19.56%
2016 Q1	22.62 Million EUR	-1.39%
2015 Q1	22.23 Million EUR	3.16%
2015 FY	22.94 Million EUR	6.47%
2015 Q3	22.93 Million EUR	1.64%
2015 Q4	22.94 Million EUR	0.05%
2015 Q2	22.56 Million EUR	1.49%
2014 Q3	21.42 Million EUR	3.84%
2014 Q4	21.54 Million EUR	0.6%
2014 FY	21.54 Million EUR	24.99%
2014 Q1	18.17 Million EUR	5.41%
2014 Q2	20.62 Million EUR	13.5%
2013 Q1	17.37 Million EUR	-0.14%
2013 Q3	17.28 Million EUR	-0.26%
2013 Q2	17.33 Million EUR	-0.26%
2013 FY	17.24 Million EUR	-0.93%
2013 Q4	17.24 Million EUR	-0.26%
2012 FY	17.4 Million EUR	4.12%
2012 Q2	19.66 Million EUR	3.98%
2012 Q4	17.4 Million EUR	-2.51%
2012 Q1	18.91 Million EUR	13.15%
2012 Q3	17.85 Million EUR	-9.22%
2011 Q1	13.27 Million EUR	3.44%
2011 Q3	12.09 Million EUR	-8.21%
2011 Q4	16.71 Million EUR	38.23%
2011 FY	16.71 Million EUR	30.28%
2011 Q2	13.17 Million EUR	-0.73%
2010 Q4	12.82 Million EUR	-13.82%
2010 FY	12.82 Million EUR	-2.85%
2010 Q3	14.88 Million EUR	16.68%
2010 Q2	12.75 Million EUR	-1.85%
2010 Q1	13 Million EUR	-1.55%
2009 Q3	9.48 Million EUR	5.49%
2009 Q2	8.99 Million EUR	-14.47%
2009 Q1	10.51 Million EUR	-7.2%
2009 FY	13.2 Million EUR	16.57%
2009 Q4	13.2 Million EUR	39.22%
2008 FY	11.32 Million EUR	-2.86%
2008 Q2	12.55 Million EUR	0.0%
2008 Q4	11.32 Million EUR	-3.8%
2008 Q3	11.77 Million EUR	-6.19%
2007 Q3	7.11 Million EUR	0.0%
2007 FY	11.66 Million EUR	-2.06%
2007 Q4	12.22 Million EUR	71.94%
2006 Q1	3.57 Million EUR	-4.71%
2006 Q3	4.47 Million EUR	5.62%
2006 Q4	13.02 Million EUR	191.34%
2006 FY	11.9 Million EUR	-10.3%
2006 Q2	4.23 Million EUR	18.53%
2005 Q1	3.18 Million EUR	21.36%
2005 Q4	3.74 Million EUR	0.0%
2005 FY	13.27 Million EUR	405.7%
2005 Q2	3.08 Million EUR	-3.05%
2004 Q4	2.62 Million EUR	0.0%
2004 FY	2.62 Million EUR	46.2%
2004 Q2	2.61 Million EUR	3.74%
2004 Q1	2.52 Million EUR	40.6%
2003 Q4	1.79 Million EUR	0.0%
2003 FY	1.79 Million EUR	0.0%
2002 FY	- EUR	0.0%
2001 FY	- EUR	0.0%

Peer Total Debt Comparison of Evotec SE

Name	Total Debt	Total Debt Difference
MPH Health Care AG	13.05 Million EUR	-4696.816%
Apontis Pharma AG	6 Million EUR	-10336.633%
Dermapharm Holding SE	1.08 Billion EUR	42.04%
MERCK Kommanditgesellschaft auf Aktien	9.94 Billion EUR	93.701%
PharmaSGP Holding SE	73.97 Million EUR	-746.477%
SynBiotic SE	3.68 Million EUR	-16915.076%

Global Stocks Search

Evotec SE (EVT.DE)

Total Debt Summary of Evotec SE

Annual Total Debt Chart of Evotec SE (2023 - 2001)

Historical Annual Total Debt of Evotec SE (2023 - 2001)

Peer Total Debt Comparison of Evotec SE